Lapatinib
A targeted cancer therapy that inhibits both HER2 and EGFR tyrosine kinases, used to treat HER2-positive breast cancer and studied in bladder cancer. It blocks the signaling pathways that drive cancer cell growth and proliferation.
Masse moléculaire
581,1000 g/mol
LogP
5,10
TPSA
115,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Structure 2D
Cite this structure
Embed this structure
SMILES
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
InChI
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
Molecular Formula
C29H26ClFN4O4S
HBD / HBA
2 / 9
Liaisons Rotatives
11
Atomes Lourds
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A targeted cancer therapy that inhibits both HER2 and EGFR tyrosine kinases, used to treat HER2-positive breast cancer and studied in bladder cancer. It blocks the signaling pathways that drive cancer cell growth and proliferation.
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Yes, Lapatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL554. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 208908. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="lapatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/lapatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/lapatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/lapatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="lapatinib"></drugfyi-drug>